RxDoctor Payments Data

Edward Rydzak, MD

Gastroenterology · Savannah, GANPI 1639157266

Payments from drug & device makers

$4,674in general payments, 2019–2025

Across 265 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$483
  • Gilead$356
  • Takeda Pharmaceuticals U.S.A., Inc.$184
  • Bristol Myers Squibb$176
  • Johnson & Johnson$170
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,674 in reported general payments places this provider in the 55th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$211,277
Medicare patients
421
Services billed
5,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab13$87,484
XifaxanRifaximin21$69,024
LinzessLinaclotide22$23,949
ZenpepLipase/Protease/Amylase12$21,804
Mesalamine18$5,989
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates64$4,460
Pantoprazole Sodium144$1,530
Omeprazole77$1,174
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg26$607
Azathioprine12$584
Dicyclomine Hcl34$377
Esomeprazole Magnesium20$371
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl23$347
Ondansetron Hcl18$260
Sucralfate19$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$483$69,02421 claims
AbbVieLinzess$2,285$23,94922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →